Mycophenolic acid predose concentrations and renal function in a mouse model for progressive renal fibrosis

Therapeutic Drug Monitoring

Volumn 32, Issue 1, 2010, Pages 73-78

  Brandhorst, Gunnar ^a   Brehmer, Franziska ^a   Petrova, Darinka T ^a   Gross, Oliver ^a   Miosge, Nicolai ^a   Armstrong, Victor W ^a   Oellerich, Michael ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Alport syndrome; COL4A3; Mycophenolate mofetil; Mycophenolic acid; Renal fibrosis

Indexed keywords

CREATININE; DRUG METABOLITE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG MECHANISM; HISTOPATHOLOGY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOMNOLENCE; SURVIVAL TIME; UREA NITROGEN BLOOD LEVEL;

ANIMALS; AUTOANTIGENS; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MICE; MICE, KNOCKOUT; MYCOPHENOLIC ACID; SURVIVAL RATE;

EID: 75649108541     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181c91fc4     Document Type: Article

References (32)

1. Shipkova M, Armstrong VW, Oellerich M, et al. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol. 2005;1:505-526.
2. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005; 353:2219-2228.
3. Spetie DN, Tang Y, Rovin BH, et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int. 2004;66:2411-2415.
4. Copeland JW, Beaumont BW, Merrilees MJ, et al. Epithelial-to-mesenchymal transition of human proximal tubular epithelial cells: effects of rapamycin, mycophenolate, cyclosporin, azathioprine, and methylprednisolone. Transplantation. 2007;83:809-814.
5. Merville P, Berge F, Deminiere C, et al. Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant. 2004;4:1769-1775.
6. Morales JM. Immunosuppressive treatment and progression of histologic lesions in kidney allografts. Kidney Int Suppl. 2005;S124-S130.
7. Morath C, Schwenger V, Beimler J, et al. Antifibrotic actions of mycophenolic acid. Clin Transplant. 2006;20(Suppl 17):25-29.
8. Waller JR, Brook NR, Bicknell GR, et al. Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration. Transplant Proc. 2005; 37:164-166.
9. Johnsson C, Gerdin B, Tufveson G. Effects of commonly used immuno-suppressants on graft-derived fibroblasts. Clin Exp Immunol. 2004;136: 405-412.
10. Roos N, Poulalhon N, Farge D, et al. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther. 2007;321:583-589.
11. Boor P, Sebekova K, Ostendorf T, et al. Treatment targets in renal fibrosis. Nephrol Dial Transplant. 2007;22:33913407.
12. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117:524-529.
13. Kondo S, Shimizu M, Urushihara M, et al. Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat. J Am Soc Nephrol. 2006;17:783-794.
14. Yang J, Dai C, Liu Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol. 2002;13:2464-2477.
15. Yu L, Border WA, Anderson I, et al. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int. 2004;66:1774-1784.
16. Cosgrove D, Meehan DT, Grunkemeyer JA, et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev. 1996;10:2981-2992.
17. Gross O, Beirowski B, Koepke ML, et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 2003;63:438-446.
18. Brandhorst G, Streit F, Goetze S, et al. Quantification by liquid chroma-tography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites. Clin Chem. 2006;52:1962-1964.
19. Streit F, Shipkova M, Armstrong VW, et al. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. Clin Chem. 2004;50:152-159.
20. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int. 1984;26: 137-143.
21. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. 1998;54:1570-1580.
22. Alport AC. Hereditary familial congenital haemorrhagic nephritis. BMJ. 1927;1:504-506.
23. Ninichuk V, Gross O, Reichel C, et al. Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol. 2005;16:977-985.
24. Badid C, Vincent M, McGregor B, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int. 2000;58:51-61.
25. Badid C, Desmouliere A, Laville M. Mycophenolate mofetil: implications for the treatment of glomerular disease. Nephrol Dial Transplant. 2001; 16:1752-1756.
26. Fujihara CK, Malheiros DM, Zatz R, et al. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int. 1998;54: 1510-1519.
27. Remuzzi G, Zoja C, Gagliardini E, et al. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol. 1999;10: 1542-1549.
28. Romero F, Rodriguez-Iturbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int. 1999;55:945-955.
29. Kramer S, Loof T, Martini S, et al. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol. 2005;289: F359-F368.
30. Zhang C, Zhu Z, Wang G, et al. Effects of mycophenolate mofetil on renal interstitial fibrosis after unilateral ureteral obstruction in rats. J Huazhong Univ Sci Technolog Med Sci. 2003;23:269-270, 282.
31. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
32. Heller T, Geide A, Bonitz U, et al. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model. Transplantation. 2008;85:739-747.